CASI Pharmaceuticals (FRA:ENM) Total Liabilities: €53.74 Mil (As of Dec. 2025)

What is CASI Pharmaceuticals Total Liabilities?

CASI Pharmaceuticals FRA:ENM 29 Total Liabilities is €53.74 Mil as of Dec. 2025. GuruFocus rates FRA:ENM with a GF Score™ of 29/100 and a GF Value™ of €11.74. The stock has 5 warning signs investors should review.

CASI Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 was €53.74 Mil.

CASI Pharmaceuticals's quarterly Total Liabilities increased from Jun. 2025 (€44.66 Mil) to Sep. 2025 (€45.20 Mil) and increased from Sep. 2025 (€45.20 Mil) to Dec. 2025 (€53.74 Mil).

CASI Pharmaceuticals's annual Total Liabilities increased from Dec. 2023 (€46.86 Mil) to Dec. 2024 (€49.49 Mil) and increased from Dec. 2024 (€49.49 Mil) to Dec. 2025 (€53.74 Mil).

CASI Pharmaceuticals Total Liabilities Related Terms

CASI Pharmaceuticals Total Liabilities Historical Data

* Premium members only.

The historical data trend for CASI Pharmaceuticals's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CASI Pharmaceuticals Total Liabilities Chart

CASI Pharmaceuticals Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Total Liabilities

Get a 7-Day Free Trial

26.85

27.66

46.86

49.49

53.74

CASI Pharmaceuticals Quarterly Data
	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25
Total Liabilities	Get a 7-Day Free Trial															49.49	45.22	44.66	45.20	53.74

29GF Score

CASI Pharmaceuticals Inc FRA:ENM

Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

CASI Pharmaceuticals Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

CASI Pharmaceuticals's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	42.418	+	(1.231	+	10.095
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	53.74

Total Liabilities	=	Total Assets (A: Dec. 2025 )	-	Total Equity (A: Dec. 2025 )
	=	21.905	-	-31.839
	=	53.74

CASI Pharmaceuticals's Total Liabilities for the quarter that ended in Dec. 2025 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	42.418	+	(1.231	+	10.095
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit	+	NonCurrent Deferred Income Tax)
	+	0	+	0	+	0)
	=	53.74

Total Liabilities	=	Total Assets (Q: Dec. 2025 )	-	Total Equity (Q: Dec. 2025 )
	=	21.905	-	-31.839
	=	53.74

Frequently Asked Questions Learn more about Total Liabilities →

What does a Total Liabilities of €53.74 Mil mean?

CASI Pharmaceuticals (FRA:ENM) has a Total Liabilities of €53.74 Mil as of Dec. 2025. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CASI Pharmaceuticals and its competitors.

Is CASI Pharmaceuticals' Total Liabilities too high?

CASI Pharmaceuticals' current Total Liabilities is €53.74 Mil. Overall, CASI Pharmaceuticals has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.

How does CASI Pharmaceuticals' Total Liabilities compare to ITRMF and OGEN?

CASI Pharmaceuticals' Total Liabilities of €53.74 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Total Liabilities for a Biotechnology company?

A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Total Liabilities mean?

A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for CASI Pharmaceuticals and its competitors. CASI Pharmaceuticals's current Total Liabilities is €53.74 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is CASI Pharmaceuticals stock overvalued right now?

CASI Pharmaceuticals (FRA:ENM) has a current Total Liabilities of €53.74 Mil. The stock's GF Value™ is €11.74, compared to a current price of €1.54 — trading 86.9% below its estimated fair value. The current Total Liabilities is €53.74 Mil. CASI Pharmaceuticals' overall GF Score™ is 29/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Total Liabilities calculated?

Total Liabilities is calculated from a company's financial statements. For CASI Pharmaceuticals (FRA:ENM), the current Total Liabilities is €53.74 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CASI Pharmaceuticals (FRA:ENM) Overvalued in 2026?

Based on GuruFocus' analysis, CASI Pharmaceuticals stock appears to be undervalued. The current stock price of €1.54 is trading 86.9% below its estimated GF Value™ of €11.74.

Key valuation signals for FRA:ENM:

Total Liabilities: €53.74 Mil
GF Value™: €11.74 vs. price of €1.54 (86.9% below fair value)
GF Score™: 29/100 with 5 warning signs

No single metric tells the full story. See the FRA:ENM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CASI Pharmaceuticals Business Description

Industry Healthcare Biotechnology

Comparable Companies ITRMF OGEN AZTR VRAX BBLG SLXN VIVS PKTX CDT CLDI VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CASIF:USA

Address Jianguo Road, No. 81, Room 1701-1702, China Central Office Tower 1, Huamao Office Building, Chaoyang District, Beijing, CHN, 100025

Website https://www.casipharmaceuticals.com

CASI Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing CID-103, an anti-CD38 monoclonal antibody, for patients with organ transplant rejection and autoimmune diseases. Additionally, the company manages its other assets, including EVOMELA, FOLOTYN, CNCT19, BI-1206, and CB-5339, with a primary strategic emphasis on advancing CID-103 toward key clinical and regulatory milestones. It also distributes YuTuo (Zimberelimab), a fully human anti-PD-1 monoclonal antibody for patients with relapsed or refractory classical Hodgkin's lymphoma and recurrent or metastatic cervical cancer. Geographically, the company's revenue is solely generated in Mainland China.

29GF Score

Get the complete analysis for FRA:ENM

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.54

Price

€11.74

GF Value

View FRA:ENM Analysis

See Total Liabilities data for all stocks →